Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.
Marksans Pharma's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is
-24.48%.
Marksans Pharma Margin of Safety % (DCF Dividends Based) Related Terms
BOM:524404 vs LLY, JNJ, ABBV: Margin of Safety % (DCF Dividends Based) Comparison
For the Drug Manufacturers - General subindustry, Marksans Pharma's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marksans Pharma Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:
* The bar in red indicates where Marksans Pharma's Margin of Safety % (DCF Dividends Based) falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Margin of Safety % (DCF Dividends Based) of -24.48% mean?
Marksans Pharma (BOM:524404) has a Margin of Safety % (DCF Dividends Based) of -24.48% as of Jul. 24, 2026. Margin of Safety % (DCF Dividends Based) is the percent difference between the current price and the intrinsic DCF Dividends price. View historical data on Marksans Pharma.
Is Marksans Pharma's Margin of Safety % (DCF Dividends Based) too high?
Marksans Pharma's current Margin of Safety % (DCF Dividends Based) is -24.48%. Overall, Marksans Pharma has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Marksans Pharma's Margin of Safety % (DCF Dividends Based) compare to LLY and JNJ?
Marksans Pharma's Margin of Safety % (DCF Dividends Based) of -24.48% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Margin of Safety % (DCF Dividends Based) for a Drug Manufacturers company?
A good Margin of Safety % (DCF Dividends Based) depends on the Drug Manufacturers industry context. However, Margin of Safety % (DCF Dividends Based) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Margin of Safety % (DCF Dividends Based) mean?
A high Margin of Safety % (DCF Dividends Based) can signal that a stock is expensive relative to its fundamentals. Margin of Safety % (DCF Dividends Based) is the percent difference between the current price and the intrinsic DCF Dividends price. View historical data on Marksans Pharma. Marksans Pharma's current Margin of Safety % (DCF Dividends Based) is -24.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marksans Pharma stock overvalued right now?
Based on GuruFocus' analysis, Marksans Pharma (BOM:524404) is currently considered Fairly Valued. The stock's GF Value™ is ₹230.03, compared to a current price of ₹246.50 — trading 7.2% above its estimated fair value. The current Margin of Safety % (DCF Dividends Based) is -24.48%. Marksans Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Margin of Safety % (DCF Dividends Based) calculated?
Margin of Safety % (DCF Dividends Based) is calculated from a company's financial statements. For Marksans Pharma (BOM:524404), the current Margin of Safety % (DCF Dividends Based) is -24.48% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marksans Pharma (BOM:524404) Overvalued in 2026?
Based on GuruFocus' analysis, Marksans Pharma stock appears to be overvalued.
The current stock price of ₹246.50 is trading 7.2% above its estimated GF Value™ of ₹230.03.
GuruFocus considers Marksans Pharma to be Fairly Valued.
Key valuation signals for BOM:524404:
Margin of Safety % (DCF Dividends Based): -24.48%
GF Value™: ₹230.03 vs. price of ₹246.50 (7.2% above fair value)
No single metric tells the full story. See the BOM:524404 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
85GF Score
Get the complete analysis for BOM:524404
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524404 has been successfully added to your 
